Phase II Trial of Sorafenib in Combination with Carboplatin and Paclitaxel in Patients with Metastatic Uveal Melanoma: SWOG S0512

BACKGROUND: Sorafenib, a multikinase inhibitor of cell proliferation and angiogenesis, inhibits the mitogen-activated protein kinase pathway that is activated in most uveal melanoma tumors. This phase II study was conducted by the SWOG cooperative group to evaluate the efficacy of sorafenib in combi...

Descripción completa

Detalles Bibliográficos
Autores principales: Bhatia, Shailender, Moon, James, Margolin, Kim A., Weber, Jeffrey S., Lao, Christopher D., Othus, Megan, Aparicio, Ana M., Ribas, Antoni, Sondak, Vernon K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3511501/
https://www.ncbi.nlm.nih.gov/pubmed/23226204
http://dx.doi.org/10.1371/journal.pone.0048787

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3511501/
https://www.ncbi.nlm.nih.gov/pubmed/23226204
http://dx.doi.org/10.1371/journal.pone.0048787

Ejemplares similares